A new treatment offers hope for advanced-stage, metastatic castration-resistant prostate cancer (mCRPC). Therapy options are limited for men with advanced prostate cancer.
In the featured article of The Journal of Nuclear Medicine's, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium-225 (225Ac)-labeled targeted alpha therapy of patients with prostate-specific membrane antigen (PSMA)-positive tumors.
The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.
Salvage therapy results show treatment with 100kBq/kg 225Ac-PSMA-617 is tolerated by patients and demonstrates a promising anti-tumor response. Also, it was determined that repeated treatments at intervals of eight weeks might lead to continuing tumor control.
"We developed a treatment protocol that presents a promising trade-off between toxicity and anti-tumor activity of PSMA-directed targeted alpha therapy," says Kratochwil.
"However, our current results present only a starting-dose that, on the one hand, has still to be optimized and, on the other hand, needs further studies to evaluate its efficacy. Ultimately, there could be a new treatment modality to improve symptomatic patients and prolong survival."
Looking ahead, Kratochwil states, "If PSMA-targeted alpha therapy keeps its promise, it may earn a significant place in therapeutic nuclear medicine. However, it is the nature of all molecular targeting therapies that they can only be useful if the target is sufficiently expressed in the tumors.
Thus, molecular imaging using PSMA-PET/CT also has an important role as a stratification criterion, and the 'theranostic' concept [combining diagnostic imaging of a biomarker with precise therapy] may be an additional motivation to establish PSMA-PET/CT as a routinely available imaging modality."